Generic Name: halobetasol propionate and tazarotene
Brand Name: TBC
Manufacturer: Bausch Health, Canada Inc.
Indications: Psoriasis, moderate to severe plaque
Manufacturer Requested Reimbursement Criteria1:
Topical treatment of moderate-to-severe plaque psoriasis in adult patients.
Submission Type: New
Project Status: Pending
Call For Patient Input: January 7, 2019
Patient Input Closed: February 26, 2019
Anticipated Date: February 4, 2019
Fee Schedule: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.